MedPath

Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Clinical Trials
Related News

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2
Not yet recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Chest Radiography
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Placebo Administration
Procedure: Positron Emission Tomography
Radiation: Total-Body Irradiation
First Posted Date
2025-05-02
Last Posted Date
2025-05-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
244
Registration Number
NCT06954987

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 3
Not yet recruiting
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Interventions
First Posted Date
2025-04-24
Last Posted Date
2025-04-24
Lead Sponsor
BeiGene
Target Recruit Count
630
Registration Number
NCT06943872

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)

Phase 2
Not yet recruiting
Conditions
Core Binding Factor Acute Myeloid Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
First Posted Date
2025-04-09
Last Posted Date
2025-04-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
162
Registration Number
NCT06917911

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Phase 2
Not yet recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Procedure: Allogeneic hematopoietic stem cell transplantation
First Posted Date
2025-04-01
Last Posted Date
2025-04-15
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
100
Registration Number
NCT06903702
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities), Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4
Not yet recruiting
Conditions
Relapsed/Refractory AML
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-03-25
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
172
Registration Number
NCT06763666
Locations
🇨🇳

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Newly-diagnosed Pediatric T-cell ALL Protocol

Phase 2
Not yet recruiting
Conditions
Acute Lymphoblastic Leukemia
Childhood Leukemia, Acute Lymphoblastic
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Interventions
First Posted Date
2025-03-04
Last Posted Date
2025-03-14
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
610
Registration Number
NCT06855810
Locations
🇨🇳

Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China

🇨🇳

Anhui Provincial Children's Hospital, Hefei, Anhui, China

🇨🇳

Chongqing Medical University Affiliated Children's Hospital, Chongqing, Chongqing, China

and more 23 locations

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

Phase 3
Not yet recruiting
Conditions
Leukemia, Myeloid, Acute
Interventions
Drug: Placebo
First Posted Date
2025-02-28
Last Posted Date
2025-05-04
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
600
Registration Number
NCT06852222
Locations
🇮🇱

Hadassah University Hospita Ein Kerem, Jerusalem, Israel

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Phase 3
Recruiting
Conditions
CLL
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2025-02-26
Last Posted Date
2025-05-16
Lead Sponsor
BeiGene
Target Recruit Count
250
Registration Number
NCT06846671
Locations
🇳🇿

North Shore Hospital, Auckland, New Zealand

🇺🇸

Cleveland Clinic Florida, Weston, Florida, United States

🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

and more 96 locations

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1
Not yet recruiting
Conditions
T-cell-prolymphocytic Leukemia
Cutaneous T-Cell Lymphoma Refractory
Interventions
First Posted Date
2025-02-06
Last Posted Date
2025-04-15
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
12
Registration Number
NCT06810778
Locations
🇺🇸

David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, United States

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase 1
Not yet recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Radiation: Actinium Ac 225 Lintuzumab
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
First Posted Date
2025-01-31
Last Posted Date
2025-05-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT06802523
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy